Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG889

—

b59fdf71-3651-5bbd-988b-563c77069824

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • G2M_CHECKPOINT+0.451
  • E2F_TARGETS+0.436
  • TGF_BETA_SIGNALING+0.255
  • TNFA_SIGNALING_VIA_NFKB+0.248
  • MTORC1_SIGNALING+0.215
  • DNA_REPAIR+0.201
  • SPERMATOGENESIS+0.195
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.171
  • CHOLESTEROL_HOMEOSTASIS+0.162
  • MYC_TARGETS_V2+0.162

Top 10 suppressed

  • ALLOGRAFT_REJECTION-0.382
  • INTERFERON_GAMMA_RESPONSE-0.375
  • OXIDATIVE_PHOSPHORYLATION-0.371
  • INTERFERON_ALPHA_RESPONSE-0.368
  • HEDGEHOG_SIGNALING-0.350
  • WNT_BETA_CATENIN_SIGNALING-0.263
  • ADIPOGENESIS-0.255
  • COMPLEMENT-0.247
  • FATTY_ACID_METABOLISM-0.235
  • IL6_JAK_STAT3_SIGNALING-0.232

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1s_150324_5a
medullo-epn-umap@date-based
EPNSupratentorial EPN0.805
2SRR5088878
melanoma-umap@29
——0.797
3SRR10842373
melanoma-umap@29
——0.763
4MNG495
mng-umap@100
——0.763
5SRR12202460
bladder-landscape@3
——0.762
65572a203-73b9-4a85-b47d-af228abca5b1
melanoma-umap@29
——0.756
7TCGA-OR-A5JA-01
acc-tcga-pancan-2018@2018
Adrenocortical CarcinomaAdrenocortical Carcinoma, Usual Type0.747
8SRR25043634
head-neck@1
——0.742
9MDT-AP-3185
medullo-epn-umap@date-based
MedMedulloblastoma0.735
10TCGA-63-A5MH-01A-12R-A27Q-07
lung-landscapes@6
—cohortSQ10.732

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 20 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
G2M_CHECKPOINT0.451Inavolisib— uncovered
E2F_TARGETS0.436Inavolisib— uncovered
TGF_BETA_SIGNALING0.255Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.248Inavolisib— uncovered
MTORC1_SIGNALING0.215Inavolisib— uncovered
DNA_REPAIR0.201Idelalisib— uncovered
SPERMATOGENESIS0.195Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.171Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.162Remibrutinib— uncovered
MYC_TARGETS_V20.162Idelalisib— uncovered
MYC_TARGETS_V10.150Inavolisib— uncovered
MITOTIC_SPINDLE0.144Inavolisib— uncovered
P53_PATHWAY0.116Idelalisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.113Idelalisib— uncovered
APOPTOSIS0.081Idelalisib— uncovered
ANDROGEN_RESPONSE0.039Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.031Inavolisib— uncovered
UV_RESPONSE_UP0.015Idelalisib— uncovered
GLYCOLYSIS0.013Inavolisib— uncovered
PANCREAS_BETA_CELLS0.007Cobimetinib— uncovered